Field report describes posttreatment lesions after tecovirimat therapy for mpox in New York City

A field report from New York City describes the occurrence of posttreatment lesions in patients with mpox who received tecovirimat therapy. The report does not specify the study phase, sample size, comparator group, or primary outcome measures. No quantitative results, effect sizes, or statistical measures are provided; the finding is described qualitatively as 'posttreatment lesions were described'.

No safety or tolerability data, including adverse events, serious adverse events, or treatment discontinuations, are reported. The report does not list specific methodological limitations, but the absence of a comparator, sample size, and quantitative outcomes are inherent constraints.

Given the descriptive nature of this single field report, the clinical relevance for practice is not established. This observation should be interpreted as a potential signal requiring investigation in formal studies with defined populations, controls, and outcome measures before any conclusions about tecovirimat and posttreatment lesions can be drawn.